State of Alaska Department of Revenue increased its position in Hologic, Inc. (NASDAQ:HOLX) by 53.4% during the second quarter, Holdings Channel reports. The fund owned 19,132 shares of the medical equipment provider’s stock after buying an additional 6,660 shares during the period. State of Alaska Department of Revenue’s holdings in Hologic were worth $868,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in HOLX. Swiss National Bank raised its position in shares of Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock worth $43,747,000 after buying an additional 195,100 shares during the last quarter. Lincoln Capital Corp bought a new position in shares of Hologic during the fourth quarter worth $377,000. Earnest Partners LLC raised its position in shares of Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock worth $8,734,000 after buying an additional 205,138 shares during the last quarter. KAMES CAPITAL plc bought a new position in shares of Hologic during the first quarter worth $718,000. Finally, LS Investment Advisors LLC raised its position in shares of Hologic by 10.9% in the first quarter. LS Investment Advisors LLC now owns 12,890 shares of the medical equipment provider’s stock worth $548,000 after buying an additional 1,268 shares during the last quarter. 94.04% of the stock is owned by hedge funds and other institutional investors.
Shares of Hologic, Inc. (NASDAQ HOLX) opened at 44.95 on Wednesday. The company has a market capitalization of $12.59 billion, a PE ratio of 16.12 and a beta of 0.91. The firm’s 50-day moving average is $44.96 and its 200 day moving average is $42.66. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. The firm had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the company earned $0.47 earnings per share. Equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
A number of equities analysts recently weighed in on HOLX shares. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 target price for the company in a research note on Tuesday, April 4th. Leerink Swann reaffirmed an “outperform” rating and issued a $52.00 target price on shares of Hologic in a research note on Thursday, March 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $53.00 target price on shares of Hologic in a research note on Tuesday, May 9th. Barclays PLC set a $50.00 target price on shares of Hologic and gave the stock a “buy” rating in a research note on Wednesday, April 5th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $47.00 target price on shares of Hologic in a research note on Sunday, May 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. Hologic has an average rating of “Buy” and an average price target of $47.77.
In related news, Director Sally Crawford sold 16,969 shares of the firm’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $44.00, for a total transaction of $746,636.00. Following the transaction, the director now directly owns 157,305 shares of the company’s stock, valued at $6,921,420. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 10,374 shares of the firm’s stock in a transaction dated Wednesday, April 26th. The shares were sold at an average price of $44.46, for a total transaction of $461,228.04. Following the transaction, the director now directly owns 37,377 shares in the company, valued at $1,661,781.42. The disclosure for this sale can be found here. Insiders have sold 96,404 shares of company stock valued at $4,256,438 over the last quarter. Corporate insiders own 0.79% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
